undamentalytics Newsletter
Sign in

Halozyme Therapeutics, Inc. cash flow statement

In fiscal 2025, Halozyme Therapeutics, Inc.'s operations generated $652m of cash; it spent $7.0m on capital projects, leaving free cash flow of $645m. It returned $342m through buybacks.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−40−45−34−64−49−48−37−50134−50−8555299240389479652819
Depreciation and amortisation1211122222433611101115
Stock-based pay55681015212631363517212437435263
Capital spending111121231543151511712
Free cash flow−42−46−35−66−52−49−39−54133−54−8953298235373468645806
Free cash flow after stock pay−46−51−41−74−61−64−60−79102−90−12436277211337425593743
Share buybacks————————00200150350200402250342—
Shares issued386008101080013500———————

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: ALKS vs HALOHALO vs INSMHALO vs MDGL

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Halozyme Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Halozyme Therapeutics, Inc.